BHCBausch Health Companies Inc.
Price
-10%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growth steady, the market undecided.
Our portfolio of products falls into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified and (v) Bausch + Lomb. The following is a brief description of the Company’s segments: For additional discussion of our reportable segments, see the discussion in Item 1. “Business — Segment Information” and Note 23, “SEGMENT INFORMATION” to our audited Consolidated Financial Statements.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Bausch Health Companies Inc. (BHC) reported revenue of $2.85B in Q2 2026 (quarter ended Jun 30, 2026), up 13% from the same quarter a year earlier. That came with net income of $260M (9.1% of revenue). For the full year FY2025, revenue was $10.3B (+6.7% year on year) and net income $120M. Its largest region in Q4 2024 (quarter ended Dec 31, 2024) was United Statesand Puerto Rico at $1.54B, 60% of the disclosed total, well ahead of Other Countries at 11%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 29, 2026(877) 281-6642 (toll free)Earnings release · press release
- Jul 1, 2026On June 26, 2026, Mr. Michael Goettler notified Bausch Health Companies Inc. (the “Company”) of his decision to resign from the Board of Directors (the “Board”), effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC. Mr. Goettler’s resignation was not …Director or officer change · Form 8-K
- Apr 29, 2026(877) 281-6642 (toll free)Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q4 2024 · $2.56BThe company’s own SEC segment disclosure.
- United States and Puerto Rico$1.54B60%
- Other Countries$292.0M11%
- China$145.0M6%
- Canada$109.0M4%
- Poland$94.0M4%
- Mexico$67.0M3%
- Other (8)$312.0M12%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #13 of 41 by RyuScore